low-risk expans power tavr procedur earli read
repeat last quarter tavr result crush
street estim third quarter underli tavr growth similar
come toward higher end compani outlook year
clear strong result spring impact volum
quarter lumpi tough estim data halo effect
sustain near-to-intermedi term optim compani
provid earli read tavr procedur growth anticip
return low double-digit growth beyond low-risk expans ou penetr
japan momentum ncd chang continu provid foundat support
busi like ultim feel mani ww
aortic valv probabl market even warrant
current valuat feel lot posit news trial regulatori reimburs
strong commerci launch mitral alreadi built stock price
valuat thu neutral even though think ew continu beat
surpris us dimmer outlook mitral sale year mar
otherwis perfect print manag expect mitral revenu
target last decemb premium-pr strategi control launch
pascal rein site activ frankli dont think shortfal realli
matter near-term overal thv number beat longer term feel
strong mitral trial reimburs multibillion dollar launch alreadi
contain current share price anyth mitral replac goe wrong
share could pull back even stellar low risk aortic result
balanc optimist tavr outlook continu oper leverag drive
estim higher edward share break high
like remain elev short-term upcom decemb analyst day
may prove anoth stock catalyst revis model share trade
ep forecast nearli doubl peer group averag feel
current valuat continu price mani posit prefer
attract entri point thought doubt get one next month
tavr side big news delay target enrol complet
earli tavr asymptomat trial expans
popul interest weve view long-term play
mayb even tough sell popul mortal alreadi low
multipl year
tweak forecast rais tavr estim solid
result fiscal model tavr revenu growth vs high
valuat maintain neutral rate risk page
idc btig estim compani document
million except per share amount
edward rate neutral view edward well-round aortic mitral tricuspid portfolio
make competit long-term confid trans-sept mitral replac product
could closer previous estim near-term number headwind time product launch
competit entri skew optic see real urgenc share feel
share market cap price mani thing go right bake success mitral program
stabl procedur growth price
expans current tam
cut reimburs
edward major market
surgic heart valv
multipl area critic care
three import
result stock trade almost
entir thv result
consolid revenu outperform forecast heel better tavr sale specif ww
tavr tmtt revenu came estim underli tavr growth
similar growth seen compani longer break vs ou tavr perform
dollar manag estim tavr procedur grew y/i basi ew growth in-lin
market ou tavr procedur grew y/i basi ew perform also compar
 edward observ growth broad-bas similar improv high low volum center
turn mitral report sale quarter consensu in-lin forecast
sale improv report ytd mitral sale trend
manag intern estim pascal price premium strategi control launch limit site adopt
adj gross margin sequenti model year-over-year improv gross
margin driven currenc product mix off-set spend new eu regul devic previous
discuss adj sg margin better forecast dollar basi sg spend
increas y/i due higher thv salesforc expens growth eu mitral salesforc meanwhil adj
margin lower forecast margin increas y/i due invest thv
program adj ebit margin dip sequenti lower tax rate vs forecast help
ep sum adj ep higher model
revenu rais revenu estim princip tavr beat turn drive adj ep
forecast higher adj ep forecast move
model tavr growth vs previous incorpor bit gross margin pressur fx
hedg benefit seen dissip forecast revenu growth vs previous
adj ep increas
actualsbtig estimate variancethv tmtt revenu heart valv revenu million adj consign revenu revenu expens expens net dilut gross margin bpssg margin bpsr spend bpsadj ebit margin bpstax rate bpssourc btig research estim compani filingsal metric present herein non-gaap basi margin estim non-gaap basi varianc
edward rate neutral feel ew current market capit price lead market share
fulli penetr matur tavr market year signific mitral sale btig provid price target
neutral-r stock risk includ competit patent litig slippag product timelin chang procedur
reimburs futur devic data fda possibl multipl contraction/expans
exhibit comp tabl larg cap med-tech compani
newnewold growth incom ep growth btig research estim compani filingsntm johnsonjnjnot bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us thv y/i ou thv y/i tmtt y/i heart valv y/i y/i gaap net y/i non-gaap revenu us thv y/i ou thv y/i tmtt y/i heart valv y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
